Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: Effects on clinical outcome and efficacy of adjuvant chemotherapy
Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: Effects on clinical outcome and efficacy of adjuvant chemotherapy
复制标题
DOI：
10.1002/jso.1033
复制
发表时间：
2001-03-01
影响因子：
2.5
通讯作者：
Tamura, K
中科院分区：
文献类型：
--
作者：
Nio, Y;Dong, M;Tamura, K
背景与目的：p53抑癌基因具有双重作用，既可作为细胞凋亡的触发因子，又可作为DNA修复的启动因子。Bcl-2对p53基因诱导的细胞凋亡具有保护作用。这些事实表明，这些基因在各种肿瘤的发生和发展中的重要作用。本研究旨在评估p53和Bcl-2蛋白（pBcl-2）表达的可切除的浸润性导管癌（IDC）的pancreatic.Methods：本研究包括63 IDC，这是1982年至1998年之间切除的意义。结果：63例IDC中pBcl-2阳性表达16例（25.4%），p53阳性表达32例（50.8%），但pBcl-2与p53的表达无明显相关性。虽然p53表达对患者的生存没有任何显著影响，但pBcl-2（+）患者的生存率高于pBcl-2（-）患者，这表明pBcl-2表达比p53表达对患者的生存有更显著的影响。另一方面，辅助化疗（ACT）组和单纯手术（SA）组之间的生存曲线无差异。pBcl-2表达对ACT疗效无影响，p53（+）IDC患者ACT组生存率明显高于SA组，结论：pBcl-2表达可作为IDC患者的预后指标，而p53表达可作为预测IDC患者辅助化疗疗效的指标。(C)2001 Wiley-Liss，Inc.
Background and Objectives: p53 tumor suppressor gene has a dual role as a trigger of apoptosis and as an initiator of DNA repair. The Bcl-2 can work to protect cells from apoptosis, which is induced by p53 gene. These facts suggest the significant role of these genes in the genesis and progression of various tumors. The present study was designed to assess the significance of p53 and Bcl-2 protein (pBcl-2) expression on resectable invasive ductal carcinoma (IDC) of the pancreas.Methods: The present study included 63 IDCs, which were resected between 1982 and 1998. pBcl-2 and p53 were stained immunohistochemically with monoclonal antibodies.Results: pBcl-2 was expressed in 16 (25.4%), and p53 was positively expressed in 32 out of 63 IDCs (50.8%); however, expression of pBcl-2, did not necessarily correlate with that of p53. Although p53 expression did not show any significant influence on the patients' survival, pBcl-2(+) patients showed a higher survival than pBcl-2(-) patients for both p.53(+) and p53(-) patients, which suggested that pBcl-2 expression had a more significant effect on the survival of patients than p53 expression. On the other hand, there were no differences in the survival curve between the adjuvant chemotherapy (ACT) group and the surgery alone (SA) group. pBcl-2 expression had no influence on the effect of ACT, the ACT group showed a significantly better survival than the SA group for p53(+) IDC patients.Conclusions: pBcl-2 expression is a beneficial prognostic factor for patients with IDC, whereas p53 expression may be beneficial in the prediction of the effects of adjuvant chemotherapy on patients with IDC. (C) 2001 Wiley-Liss, Inc.